Palo Alto, CANCT06827990Now EnrollingIRB Ready

Aortic Dissection Clinical Trial in Palo Alto, CA

Access cutting-edge aortic dissection treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by W.L.Gore & Associates

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access aortic dissection specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related aortic dissection treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this aortic dissection clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Aortic Dissection Study in Palo Alto

To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

Sponsor: W.L.Gore & Associates

Who Can Participate

Inclusion Criteria

- Primary Arm: The subject is/has:
De novo Type A aortic dissection (≤30 days from symptom onset to index endovascular procedure) compatible with the treatment requirements of the ASG device.
Primarily intended to be treated by placement of the ASG device in the ascending aorta. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator.
Anatomic compatibility of the ascending aorta required for implanting the ASG device: a) Proximal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium. ii. Total aortic diameter between 27mm - 48mm iii. Landing zone cannot be heavily calcified or thrombosed. b) Distal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium. c) Adequate aortic length
The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:
≥80 years of age
Body mass index (BMI) ≥ 35 kg/m2
History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised pulmonary function tests (PFT) on spirometry or other factors as determined by the Investigator)
Prior Cardiac Surgery
Hostile Chest (VARC-2 Definition)
Clinical Frailty Scale 3-7
Clinical malperfusion (head, gut, lower extremity)
Transfusion is not possible (e.g., Jehovah's Witness)
Renal Dialysis prior to aortic dissection
Chronic renal insufficiency (eGFR\<60 without dialysis or other documented history of chronic kidney disease prior to dissection)
Age ≥18 years at time of informed consent signature.
Adequate vascular access via transfemoral or retroperitoneal approach.
Informed Consent Form (ICF) signed by the subject or legally authorized representative.
Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows.

Exclusion Criteria

- Primary Arm The subject is/has:
Mechanical heart valve in the aortic position.
Aortic insufficiency grade 3 or greater confirmed during TEE pre-implant.
Indwelling intravascular device that would interfere with or result in contact with planned repair (e.g., contiguous arch graft, LVAD, TAVR device in continuity with aortic tear).
Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome).
Participation in investigational drug or medical device study within one year of enrollment unless approved by the Sponsor.
Known history of drug abuse within one year of treatment which would affect the ability to obtain follow-up.
Pregnant at time of procedure.
Active infected aorta, mycotic aneurysm.
Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).
Life expectancy \<12 months due to presence of another comorbid condition.
Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 \[HIT-2\], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and/or state should be considered exclusion if treatment plan includes implant of a TBE device).
Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.
Coronary malperfusion.
Catastrophic neurological complications in the 30 days prior to the dissection diagnosis (e.g., progressively worsening symptoms, coma, Glasgow Coma Scale \<=8).
Aortic fistula.
In circulatory shock (e.g., systolic blood pressure \<80 mmHg without inotropes, base deficit \> -10 mmol/L or -10 mEq/L) at any time prior to the initiation of the index endovascular procedure.
In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at any time prior to the initiation of the index endovascular procedure.
Clinical or radiographic signs of bowel infarction, gastrointestinal hemorrhage, or bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis) at any time prior to the initiation of the index endovascular procedure. Inclusion Criteria - Secondary Arm The subject is/has:
De novo Type A aortic dissection (≤90 days from symptom onset until first study procedure) compatible with the treatment requirements of the ASG device alone or the ASG device in combination with the TBE device in the Zone 0 position.
Primarily intended to be treated by placement of the ASG device in the ascending aorta or ASG device in combination with the TBE device in the ascending aorta and aortic arch. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator.
Anatomic requirements for intended treatment with the ASG device alone or in combination with the TBE device. a) Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device alone) i. Proximal Aortic Landing Zone:
Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium.
Total aortic diameter between 27mm - 48mm.
Landing zone cannot be heavily calcified or thrombosed. ii. Distal Aortic Landing Zone: <!-- -->
Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium. iii. Adequate aortic length
Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device and TBE device) i. Proximal Aortic Landing Zone: <!-- -->
Primary entry tear must be identified in Zone 0-5.
Landing zone is native aorta.
Primary entry tear location is ≥2cm distal to the most distal coronary artery ostium.
Proximal landing zone must be ≥2cm in the ascending aorta.
Landing zone cannot be heavily calcified or thrombosed.
Total aortic landing zone diameter 27mm - 48mm. ii. Branch Vessel Landing Zone: <!-- -->
Length of ≥2.5 cm proximal to first major branch vessel.
Target branch vessel inner diameters of 11-18 mm.
Target branch vessel landing zone must be in native vessel that cannot be heavily calcified or thrombosed.
The distal 15mm landing zone cannot be dissected.
The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:
≥80 years of age
BMI ≥ 35 kg/m2
History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised PFTs on spirometry or other factors as determined by the Investigator)
Prior Cardiac Surgery
Hostile Chest (VARC-2 Definition)
Clinical Frailty Scale 3-9
Clinical malperfusion (head, gut, lower extremity)
Transfusion is not possible (e.g., Jehovah's Witness)
Renal Dialysis prior to aortic dissection
Chronic renal insufficiency (eGFR\<60 without dialysis or other documented history of chronic kidney disease prior to dissection)
Age ≥18 years at time of informed consent signature.
Adequate vascular access via transfemoral or retroperitoneal approach.
Informed Consent Form (ICF) signed by the subject or legally authorized representative.
Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows. Exclusion Criteria - Secondary Arm: The subject is/has:
Mechanical heart valve in the aortic position.
Pregnant at time of procedure.
Active infected aorta, mycotic aneurysm.
Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).
Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 \[HIT-2\], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and/or state should be considered exclusion if treatment plan includes implant of a TBE device).
Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT06827990) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Aortic Dissection Treatment Options in Palo Alto, CA

If you're searching for aortic dissection treatment options in Palo Alto, CA, this clinical trial (NCT06827990) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced aortic dissection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all aortic dissection clinical trials near you to find additional studies recruiting in your area.

More Aortic Aneurysm Trials in Palo Alto, CA

See all aortic aneurysm clinical trials recruiting in Palo Alto — not just this study.

Browse Aortic Aneurysm Trials in Palo Alto →

Browse More Trials by Condition

Aortic Aneurysm TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA